[Sporadic primary hypothyroidism in children yesterday and today]

Area of Science:

• Pediatric Endocrinology
• Neonatal Screening
• Neurodevelopmental Disorders

Context:

• Congenital primary hypothyroidism diagnosis relies heavily on neonatal screening.
• Early L-T4 substitutive therapy is standard for affected infants.
• Despite early treatment, neurodevelopmental outcomes often differ from controls.

Purpose:

• To evaluate the impact of early diagnosis and L-T4 therapy on neurodevelopment.
• To assess the efficacy of higher L-T4 doses (10-15 mcg/Kg/day) in improving outcomes.
• To identify potential long-term risks associated with high-dose L-T4 therapy.

Summary:

• Neonatal screening enables early diagnosis and L-T4 treatment for congenital primary hypothyroidism.
• Higher L-T4 doses and earlier treatment initiation have improved IQ and neurodevelopmental scores.
• Concerns persist regarding potential behavioral and conduct issues from long-term high-dose L-T4 exposure.

Impact:

• Optimized L-T4 dosing strategies can enhance neurodevelopmental trajectories in treated infants.
• Further research is needed to monitor for and mitigate potential adverse behavioral effects.
• Advances in neonatal screening and therapeutic approaches are crucial for managing congenital hypothyroidism.